"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis (Q36318306)

13 August 2017

1 reference

title

"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

13 August 2017

0 references

0 references

1 reference

Liu C

1

1 reference

13 August 2017

Li Wan Po A

series ordinal

2

1 reference

13 August 2017

Blumhardt LD

series ordinal

3

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 June 1998

1 reference

Journal of Neurology, Neurosurgery and Psychiatry

13 August 2017

1 reference

13 August 2017

64

1 reference

13 August 2017

6

1 reference

13 August 2017

726-729

1 reference

Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2170123

A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2170123

Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2170123

More immunotherapy for multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2170123

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2170123

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2170123

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2170123

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2170123

Analysis of serial measurements in medical research

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2170123

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2170123

Studies on the natural history of multiple sclerosis. 7. Correlates of clinical change in an early bout.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2170123

An assessment of disability rating scales used in multiple sclerosis.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2170123

Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2170123

Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2170123

A note on the analysis of repeated measurements of the same subjects

22 September 2018

1 reference

12 December 2020

A neurologic rating scale (NRS) for use in multiple sclerosis

1 reference

12 December 2020

Repeated warnings re repeated measures

1 reference

12 December 2020

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

12 December 2020

Some aspects of the natural history of disseminated sclerosis

1 reference

12 December 2020

Identifiers

DOI

10.1136/JNNP.64.6.726

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

9647299

1 reference